SAN RAFAEL, Calif., Aug. 16, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that its abstract, PARP inhibition with BMN 673 in ovarian and breast cancer patients with deleterious mutations of BRCA1 and BRCA2 has been selected as a late breaking abstract by the 17th ECCO – 38th ESMO – 32nd ESTRO European Cancer Congress in Amsterdam, The Netherlands and will be presented in an oral presentation on September 29, 2013.
|European Cancer Congress Data Presentation Details|
|Date:||September 29, 2013|
|Late Breaking Abstract Title:||PARP inhibition with BMN 673 in ovarian and breast cancer patients with deleterious mutations of BRCA1 and BRCA2|
|Session:||Proffered paper session on "Breast Cancer – Early Disease" (Oral Presentation)|
|The European CanCer Organisation (ECCO) intends to publish abstracts online, for general viewing on its website ( www.ecco-org.eu).|